Association analysis of KIR/HLA genotype with liver cirrhosis, hepatocellular carcinoma, and NUC freedom in chronic hepatitis B patients

Abstract Natural killer cells are modulated through the binding of killer cell immunoglobulin-like receptors (KIRs) with human leukocyte antigen (HLA) class I ligands. This study investigated the association of KIR/HLA pairs with progression to liver cirrhosis, hepatocellular carcinoma (HCC) develop...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Satoru Joshita, Masao Ota, Hiroyuki Kobayashi, Shun-ichi Wakabayashi, Yuki Yamashita, Ayumi Sugiura, Tomoo Yamazaki, Eiji Tanaka, Takeji Umemura
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/bee59a4b231c4c6bad472af7ff358ea0
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:bee59a4b231c4c6bad472af7ff358ea0
record_format	dspace
spelling	oai:doaj.org-article:bee59a4b231c4c6bad472af7ff358ea02021-11-08T10:46:10ZAssociation analysis of KIR/HLA genotype with liver cirrhosis, hepatocellular carcinoma, and NUC freedom in chronic hepatitis B patients10.1038/s41598-021-01014-x2045-2322https://doaj.org/article/bee59a4b231c4c6bad472af7ff358ea02021-11-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-01014-xhttps://doaj.org/toc/2045-2322Abstract Natural killer cells are modulated through the binding of killer cell immunoglobulin-like receptors (KIRs) with human leukocyte antigen (HLA) class I ligands. This study investigated the association of KIR/HLA pairs with progression to liver cirrhosis, hepatocellular carcinoma (HCC) development, and nucleot(s)ide (NUC) treatment freedom in hepatitis B virus (HBV) infection. KIR, HLA-Bw, and HLA-C were genotyped in 280 Japanese HBV patients for clinical comparisons. No significant associations of KIR/HLA pairs were detected in terms of liver cirrhosis development. The KIR2DS3 positive rate was significantly higher in patients with HCC (n = 39) than in those without (n = 241) [30.8% vs. 14.9%, odds ratio (OR) 2.53, P = 0.015]. The KIR3DL1/HLA-Bw4 pair rate was significantly lower in the NUC freedom group (n = 20) than in the NUC continue group (n = 114) (25.0% vs. 52.6%, OR 0.30, P = 0.042). In conclusion, this study indicated remarkable associations of KIR/HLA with HCC development (KIR2DS3) and freedom from NUC therapy (KIR3DL1/HLA-Bw4) in HBV patients, although the number of cases was insufficient for statistical purposes. Additional multi-center analyses of larger groups are needed to clarify whether KIR/HLA pairs play a role in HBV patient status.Satoru JoshitaMasao OtaHiroyuki KobayashiShun-ichi WakabayashiYuki YamashitaAyumi SugiuraTomoo YamazakiEiji TanakaTakeji UmemuraNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-10 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Satoru Joshita Masao Ota Hiroyuki Kobayashi Shun-ichi Wakabayashi Yuki Yamashita Ayumi Sugiura Tomoo Yamazaki Eiji Tanaka Takeji Umemura Association analysis of KIR/HLA genotype with liver cirrhosis, hepatocellular carcinoma, and NUC freedom in chronic hepatitis B patients
description	Abstract Natural killer cells are modulated through the binding of killer cell immunoglobulin-like receptors (KIRs) with human leukocyte antigen (HLA) class I ligands. This study investigated the association of KIR/HLA pairs with progression to liver cirrhosis, hepatocellular carcinoma (HCC) development, and nucleot(s)ide (NUC) treatment freedom in hepatitis B virus (HBV) infection. KIR, HLA-Bw, and HLA-C were genotyped in 280 Japanese HBV patients for clinical comparisons. No significant associations of KIR/HLA pairs were detected in terms of liver cirrhosis development. The KIR2DS3 positive rate was significantly higher in patients with HCC (n = 39) than in those without (n = 241) [30.8% vs. 14.9%, odds ratio (OR) 2.53, P = 0.015]. The KIR3DL1/HLA-Bw4 pair rate was significantly lower in the NUC freedom group (n = 20) than in the NUC continue group (n = 114) (25.0% vs. 52.6%, OR 0.30, P = 0.042). In conclusion, this study indicated remarkable associations of KIR/HLA with HCC development (KIR2DS3) and freedom from NUC therapy (KIR3DL1/HLA-Bw4) in HBV patients, although the number of cases was insufficient for statistical purposes. Additional multi-center analyses of larger groups are needed to clarify whether KIR/HLA pairs play a role in HBV patient status.
format	article
author	Satoru Joshita Masao Ota Hiroyuki Kobayashi Shun-ichi Wakabayashi Yuki Yamashita Ayumi Sugiura Tomoo Yamazaki Eiji Tanaka Takeji Umemura
author_facet	Satoru Joshita Masao Ota Hiroyuki Kobayashi Shun-ichi Wakabayashi Yuki Yamashita Ayumi Sugiura Tomoo Yamazaki Eiji Tanaka Takeji Umemura
author_sort	Satoru Joshita
title	Association analysis of KIR/HLA genotype with liver cirrhosis, hepatocellular carcinoma, and NUC freedom in chronic hepatitis B patients
title_short	Association analysis of KIR/HLA genotype with liver cirrhosis, hepatocellular carcinoma, and NUC freedom in chronic hepatitis B patients
title_full	Association analysis of KIR/HLA genotype with liver cirrhosis, hepatocellular carcinoma, and NUC freedom in chronic hepatitis B patients
title_fullStr	Association analysis of KIR/HLA genotype with liver cirrhosis, hepatocellular carcinoma, and NUC freedom in chronic hepatitis B patients
title_full_unstemmed	Association analysis of KIR/HLA genotype with liver cirrhosis, hepatocellular carcinoma, and NUC freedom in chronic hepatitis B patients
title_sort	association analysis of kir/hla genotype with liver cirrhosis, hepatocellular carcinoma, and nuc freedom in chronic hepatitis b patients
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/bee59a4b231c4c6bad472af7ff358ea0
work_keys_str_mv	AT satorujoshita associationanalysisofkirhlagenotypewithlivercirrhosishepatocellularcarcinomaandnucfreedominchronichepatitisbpatients AT masaoota associationanalysisofkirhlagenotypewithlivercirrhosishepatocellularcarcinomaandnucfreedominchronichepatitisbpatients AT hiroyukikobayashi associationanalysisofkirhlagenotypewithlivercirrhosishepatocellularcarcinomaandnucfreedominchronichepatitisbpatients AT shunichiwakabayashi associationanalysisofkirhlagenotypewithlivercirrhosishepatocellularcarcinomaandnucfreedominchronichepatitisbpatients AT yukiyamashita associationanalysisofkirhlagenotypewithlivercirrhosishepatocellularcarcinomaandnucfreedominchronichepatitisbpatients AT ayumisugiura associationanalysisofkirhlagenotypewithlivercirrhosishepatocellularcarcinomaandnucfreedominchronichepatitisbpatients AT tomooyamazaki associationanalysisofkirhlagenotypewithlivercirrhosishepatocellularcarcinomaandnucfreedominchronichepatitisbpatients AT eijitanaka associationanalysisofkirhlagenotypewithlivercirrhosishepatocellularcarcinomaandnucfreedominchronichepatitisbpatients AT takejiumemura associationanalysisofkirhlagenotypewithlivercirrhosishepatocellularcarcinomaandnucfreedominchronichepatitisbpatients
_version_	1718442658559426560

Association analysis of KIR/HLA genotype with liver cirrhosis, hepatocellular carcinoma, and NUC freedom in chronic hepatitis B patients

Ejemplares similares